MAPT and Alzheimer disease: There was an increase in plasma levels of P-tau231 in some subjects without dementia who had low or intermediate tau pathology, suggesting that these early stages of AD regional pathology may be sufficient to cause the release of enough P-tau231 to be detectable in plasma.